Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2018-12-28 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
国信证券股份有限公司关于公司使用部分闲置募集资金暂时补充流动资金的核查意见
Audit Report / Information Classification · 95% confidence The document is a verification opinion from Guosen Securities regarding the use of part of idle raised funds by Te Yi Pharmaceutical Group Co., Ltd. to temporarily supplement working capital. It references regulatory rules related to securities issuance and listing, details about the raised funds from convertible bonds, and the company's board approval and independent directors' opinions. The document is a formal verification or audit opinion on the use of raised funds, not a full financial report or earnings release. It does not contain financial statements or comprehensive financial data but rather an audit or verification opinion on a specific financial action. Therefore, it fits best under the category of Audit Report / Information (AR). The document length is 2232 characters, which is consistent with a standalone audit or verification report rather than a full annual or interim report. FY 2018
2018-12-28 Chinese
关于使用部分闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 特一药业集团股份有限公司 regarding the use of part of idle raised funds for cash management. It details the board meeting resolutions, the amount and purpose of the funds, risk control measures, and opinions from independent directors, the supervisory board, and the sponsoring institution. The document does not contain financial statements or detailed financial performance data but rather discloses a corporate decision about the use of funds raised through convertible bonds. It is a regulatory announcement about capital management activities, specifically the use of idle raised funds for cash management, which fits the category of Capital/Financing Update (CAP). The document length is 4349 characters, which is relatively short and focused on a specific financing-related announcement rather than a full report or audit. Therefore, the appropriate classification is CAP with high confidence.
2018-12-28 Chinese
独立董事关于相关事项的独立意见
Board/Management Information Classification · 85% confidence The document is an independent directors' opinion on the use of idle raised funds for temporary liquidity and cash management. It references compliance with regulatory guidelines on the use of raised funds and discusses specific financial decisions but does not contain financial statements or comprehensive financial data. The document is a formal opinion related to corporate governance and fund usage rather than a full financial report or announcement of voting results. It is not a report publication announcement as it contains substantive content, but it is not an annual or interim report, earnings release, or capital update. The content fits best under Board/Management Information (MANG) as it relates to board-level decisions and independent directors' opinions on company matters.
2018-12-28 Chinese
关于第四届董事会第二次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at a board meeting of 特一药业集团股份有限公司. It details the date and attendance of the board meeting, the agenda items discussed, and the voting results on specific proposals related to the use of idle raised funds. There is no financial data, no detailed report, and no indication that this is a full management report or financial statement. The content fits the category of Board/Management Information (MANG), as it announces decisions made by the board of directors.
2018-12-28 Chinese
关于使用部分闲置募集资金进行现金管理到期赎回的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 特一药业集团股份有限公司 regarding the use of idle raised funds for cash management and the maturity redemption of such investments. It details specific financial products, amounts, terms, and actual returns, indicating a financial update related to the company's capital management activities. The document is not a full financial report like an Annual Report or Interim Report, nor is it a transcript, audit report, or legal proceeding. It is a formal announcement about the company's financing activities, specifically the use and redemption of raised funds in cash management products. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is about 5100 characters, which is sufficient for a detailed announcement rather than a brief notice or a report publication announcement.
2018-12-28 Chinese
国信证券股份有限公司关于公司使用部分闲置募集资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a verification opinion from a sponsoring securities company regarding the use of idle raised funds by a company for cash management. It references regulatory rules and approvals related to the use of raised funds, details about the raised funds, prior and current usage of idle funds for cash management, risk control measures, and the sponsor's conclusion that the usage is compliant and reasonable. The document is a formal verification or audit opinion on a specific financial activity (use of idle raised funds for cash management) rather than a full annual or interim report, earnings release, or other financial statement. It does not contain comprehensive financial statements or detailed financial results but focuses on the sponsor's audit and verification of a particular transaction or usage of funds. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles related to specific financial activities, excluding full annual reports. The document length is under 5,000 characters, but it is not merely an announcement of a report; it contains substantive verification content. Therefore, the appropriate classification is AR with high confidence. FY 2018
2018-12-28 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.